Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Zilucoplan (Zilbrysq) Peptide
Macrocyclic peptide complement C5 inhibitor for generalized myasthenia gravis.
What is Zilucoplan (Zilbrysq)?
Zilucoplan (Zilbrysq) is a complement inhibitor · neuromuscular peptide studied for generalized myasthenia gravis (anti-achr antibody positive). Below is an educational overview of Zilucoplan (Zilbrysq) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Zilbrysq
Generalized myasthenia gravis (gMG) in adults who are anti-AChR antibody positive.
A once-daily self-injection that blocks part of the immune complement system to reduce muscle weakness in myasthenia gravis.
Serious meningococcal infections — vaccinate at least 2 weeks before starting and monitor for early signs.
- •Injection-site reactions
- •Upper respiratory infections
- •Diarrhea
- •Headache
- •Meningococcal infections
- •Other serious infections from encapsulated bacteria
- •Hypersensitivity reactions
- •Unresolved Neisseria meningitidis infection
- •Not vaccinated against meningococcal disease (unless benefit outweighs risk)
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Zilucoplan (Zilbrysq) Mechanism of Action
A synthetic 15-amino-acid macrocyclic peptide that binds complement component C5 and blocks its cleavage to C5a/C5b, preventing formation of the membrane attack complex at the neuromuscular junction. Self-administered subcutaneously.
Zilucoplan (Zilbrysq) Research Areas & Benefits
Zilucoplan (Zilbrysq) Dosage & Common Research Protocols
Weight-based once-daily subcutaneous self-injection.
Protocols summarized for educational reference from published research. Not dosing guidance.
Zilucoplan (Zilbrysq) Studies & Cited Research
RAISE phase 3 trial of zilucoplan in gMG
Significant improvement in MG-ADL and QMG scores vs placebo at week 12.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Zilucoplan (Zilbrysq) Side Effects & Safety Considerations
- •FDA-approved 2023.
- •Requires meningococcal vaccination — risk of serious meningococcal infection.
- •Injection-site reactions common.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.